Skip to main content
. 2023 Jan 25;159(3):275–280. doi: 10.1001/jamadermatol.2022.6051

Figure 3. Associations Between Genetically Proxied Lipid-Lowering Drugs and Risk of Coronary Artery Disease as the Positive Control.

Figure 3.

HMGCR indicates 3-hydroxy-3-methylglutaryl CoA reductase; LDL, low-density lipoprotein; NPC1L1, Niemann-Pick C1–like 1; OR, odds ratio; PCSK9, proprotein convertase subtilisin/kexin type 9.